N-methyl-1-(pyridazin-3-yl)methanamine | 1083299-93-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-methyl-1-(pyridazin-3-yl)methanamine
• 英文别名: N-methyl-1-pyridazin-3-ylmethanamine
• CAS: 1083299-93-7
• 化学式: C₆H₉N₃
• 分子量: 123.158
• InChiKey: MQEHOFSSQIQCJV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
  申请人：OOST Thorsten

  公开号：US20140057916A1

  公开（公告）日：2014-02-27

  This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.

  这项发明涉及式1的取代4-吡啶酮及其作为中性粒细胞弹性蛋白酶活性抑制剂的用途，包含这些化合物的药物组合物，以及将其用作治疗和/或预防肺部、胃肠道和泌尿系统疾病、皮肤和眼睛的炎症性疾病以及其他自身免疫和过敏性疾病、移植物排斥反应和肿瘤性疾病的药剂的方法。
• SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20160031830A1

  公开（公告）日：2016-02-04

  Substituted dihydropyrimidinones of formula 1 which are neutrophil elastase inhibitors and useful as medicaments for the treatment of, inter alia, COPD. Exemplary is

  式1的替代二氢嘧啶酮是中性粒细胞弹性蛋白酶抑制剂，可用作治疗COPD等疾病的药物。
• [EN] BIPYRIDINE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OR CONDITIONS<br/>[FR] DÉRIVÉS DE BIPYRIDINE-SULFONAMIDE POUR LE TRAITEMENT DE MALADIES ET D'AFFECTIONS NEURODÉGÉNÉRATIVES
  申请人：NOSCIRA SA

  公开号：WO2012069428A1

  公开（公告）日：2012-05-31

  The present invention relates to novel bipyridine sulfonamide derivatives of formula (I) and their use for the treatment and/or prophylaxis of a neurodegenerative disease or condition, particularly Alzheimers disease (AD), a cardiovascular disease or a pathology involving ischemia.. Additionally, processes for preparing such derivatives5 and pharmaceutical compositions comprising them are provided.

  本发明涉及公式（I）的新型双吡啶磺胺衍生物及其用于治疗和/或预防神经退行性疾病或症状，特别是阿尔茨海默病（AD）、心血管疾病或涉及缺血的病理的用途。此外，还提供了制备这种衍生物的方法和包含它们的药物组合物。
• NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS
  申请人：Edmondson Scott D.

  公开号：US20120225886A1

  公开（公告）日：2012-09-06

  The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

  本发明提供了公式（I）的化合物，其药物组合物，以及使用它们治疗或预防通过激活β3肾上腺素受体介导的疾病的方法。
• SUBSTITUTED DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20160031825A1

  公开（公告）日：2016-02-04

  Substituted dihydropyrimidinones of formula 1 which are inhibitors of neutrophil elastase activity and which are useful as medicaments for the treatment of, inter alia, COPD. Exemplary is

  公式1的替代二氢嘧啶酮，是中性粒细胞弹性蛋白酶活性的抑制剂，可用作治疗COPD等疾病的药物。其中一个例子是：